Vaughan David Investments LLC IL Invests $88.37 Million in AstraZeneca PLC $AZNCF

Vaughan David Investments LLC IL purchased a new position in shares of AstraZeneca PLC (OTCMKTS:AZNCF) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 503,517 shares of the company’s stock, valued at approximately $88,367,000. AstraZeneca comprises approximately 1.9% of Vaughan David Investments LLC IL’s holdings, making the stock its 5th biggest holding.

A number of other large investors also recently modified their holdings of the business. Hughes Financial Services LLC acquired a new position in shares of AstraZeneca during the fourth quarter worth approximately $34,000. Alteri Wealth LLC acquired a new position in shares of AstraZeneca during the fourth quarter worth approximately $650,000. Monetary Management Group Inc. acquired a new position in shares of AstraZeneca during the fourth quarter worth approximately $1,097,000. Parallel Advisors LLC acquired a new position in shares of AstraZeneca during the fourth quarter worth approximately $2,689,000. Finally, Root Financial Partners LLC acquired a new position in shares of AstraZeneca during the fourth quarter worth approximately $622,000. 40.87% of the stock is currently owned by institutional investors and hedge funds.

AstraZeneca Stock Performance

Shares of AZNCF stock opened at $187.10 on Friday. AstraZeneca PLC has a 12 month low of $122.26 and a 12 month high of $195.00. The stock has a 50 day moving average of $187.10 and a 200-day moving average of $185.97.

AstraZeneca Company Profile

AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.

The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.